AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

MRGPRX4 Receptor Agonists and Antagonists

Summary

New drug target for treating open and closed wounds as well as chronic pain and itc

Technology Benefits

New drug target for several diseases, e.g.
Neuropathic pain
Itching
Skin inflammation
Chronic pain
Open wounds &
Closed wounds

Technology Application

The technology embodies potent and selective MRGPRX4 receptor agonists and antagonists, that may especially be used for treating pain and inflammatory conditions, such as neuropathic or chronic pain, itch, skin diseases, immune diseases, and cancer.

Detailed Technology Description

The MRGPRX (mas-related G protein-coupled receptor X) subfamily is only expressed in primates including humans and belongs to the group of orphan receptors, for which the cognate agonists are unknown.
The human MRGPRX4 receptor represents a fundamentally new drug target, and the development of potent MRGPRX4 receptor agonists, partial agonists, and antagonists / inverse agonists to be used for the treatment of MRGPRX4-associated conditions, disorders or diseases requires the design of novel drugs.

Type of Cooperation

Licensing

Others

Patent application

ID No.

5876

Country/Region

Germany

For more information, please click Here